OPKO Health, Inc. (NASDAQ:OPK) CEO Purchases $255,000.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 150,000 shares of the business’s stock in a transaction on Friday, March 28th. The shares were bought at an average price of $1.70 per share, for a total transaction of $255,000.00. Following the acquisition, the chief executive officer now owns 213,651,448 shares in the company, valued at approximately $363,207,461.60. This trade represents a 0.07 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Monday, March 17th, Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock. The stock was purchased at an average cost of $1.74 per share, for a total transaction of $348,000.00.
• On Friday, February 28th, Phillip Md Et Al Frost purchased 67,434 shares of OPKO Health stock. The stock was purchased at an average price of $1.71 per share, with a total value of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock. The shares were purchased at an average price of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.48 per share, for a total transaction of $740,000.00.

OPKO Health Price Performance

OPK opened at $1.70 on Friday. The stock has a fifty day moving average price of $1.68 and a 200 day moving average price of $1.58. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 1 year low of $1.15 and a 1 year high of $2.04. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -8.95 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million. Analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Institutional Trading of OPKO Health

Several large investors have recently added to or reduced their stakes in OPK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of OPKO Health by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock valued at $275,000 after purchasing an additional 8,064 shares during the last quarter. Two Sigma Advisers LP raised its holdings in OPKO Health by 2.3% during the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock valued at $560,000 after buying an additional 8,396 shares in the last quarter. FMR LLC lifted its position in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 12,417 shares in the last quarter. Finally, Comerica Bank increased its holdings in shares of OPKO Health by 18.2% during the 4th quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 16,369 shares during the last quarter. 64.63% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on OPK shares. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, March 19th. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Wednesday, March 12th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.